Trends in the Concomitant Prescribing of Opioids and Benzodiazepines, 2002−2014

American Journal of Preventive Medicine

Volumn 51, Issue 2, 2016, Pages 151-160

  Hwang, Catherine S ^a   Kang, Elizabeth M ^a   Kornegay, Cynthia J ^a   Staffa, Judy A ^a   Jones, Christopher M ^b   McAninch, Jana K ^a  

^a U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; OPIATE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG RELEASE; DRUG UTILIZATION; EMERGENCY WARD; EXTENDED RELEASE; FEMALE; HUMAN; IMMEDIATE RELEASE; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; PRACTICE GUIDELINE; PRESCRIPTION; RECIPIENT; SEX DIFFERENCE; TREATMENT DURATION; ADVERSE DRUG REACTION; CLINICAL PRACTICE; DRUG OVERDOSE; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; AGED; ANALGESICS, OPIOID; BENZODIAZEPINES; DRUG OVERDOSE; DRUG PRESCRIPTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS';

EID: 84962802478     PISSN: 07493797     EISSN: 18732607     Source Type: Journal    
DOI: 10.1016/j.amepre.2016.02.014     Document Type: Article

References (61)

1. 1 Jones, C.M., Mack, K.A., Paulozzi, L.J., Pharmaceutical overdose deaths, United States, 2010. JAMA 309:7 (2013), 657–659, 10.1001/jama.2013.272.
2. 2 Warner, M., Chen, L.H., Makuc, D.M., Anderson, R.N., Miniño, A.M., Drug poisoning deaths in the United States, 1980−2008. NCHS Data Brief 81 (2011), 1–8.
3. 3 Chen, L.H., Hedegaard, H., Warner, M., Drug-poisoning deaths involving opioid analgesics: United States, 1999−2011. NCHS Data Brief 166 (2014), 1–8.
4. 4 Warner, M., Chen, L.H., Makuc, D.M., Increase in fatal poisonings involving opioid analgesics in the United Sates, 1999-2006. NCHS Data Brief 22 (2009), 1–8.
5. 5 Paulozzi, L.J., Mack, K.A., Hockenberry, J.M., Vital signs: variation among states in prescribing of opioid pain relievers and benzodiazepines—United States, 2012. Morb Mortal Wkly Rep 63:26 (2014), 563–568.
6. 6 Wolf, B.C., Lavezzi, W.A., Sullivan, L.M., Flannagan, L.M., One hundred seventy two deaths involving the use of oxycodone in Palm Beach County. J Forensic Sci 50:1 (2005), 192–195, 10.1520/JFS2004194.
7. 7 Cone, E.J., Fant, R.V., Rohay, J.M., et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 27:2 (2003), 57–67, 10.1093/jat/27.2.57.
8. 8 Cone, E.J., Fant, R.V., Rohay, J.M., et al. Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. J Anal Toxicol 28:7 (2004), 217–225, 10.1093/jat/28.4.217.
9. 9 Calcaterra, S., Glanz, J., Binswanger, I.A., National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999−2009. Drug Alcohol Depend 131:3 (2013), 263–270, 10.1016/j.drugalcdep.2012.11.018.
10. 10 Jones, C.M., McAninch, J., Nonmedical-use related emergency department visits and drug overdose deaths involving the combination of opioid analgesics and benzodiazepines in the United States, 2004−2011. Am J Prev Med 49:4 (2015), 493–501, 10.1016/j.amepre.2015.03.040.
11. 11 Jones, J.D., Mogali, S., Comer, S.D., Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 125:1–2 (2012), 8–18, 10.1016/j.drugalcdep.2012.07.004.
12. 12 Compton, W.M., Volkow, N.D., Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 83:suppl 1 (2006), S4–S7, 10.1016/j.drugalcdep.2005.10.020.
13. 13 Cai R, Crane E, Poneleit K, Paulozzi L. Emergency department visits involving nonmedical use of selected prescription drugs in the United States, 2004−2008. J Pain Palliat Care Pharmacother. 2010;24(3):293−297. http://dx.doi.org/10.3109/15360288.2010.503730.
14. 14 Substance Abuse and Mental Health Services Administration. The TEDS Report: Admissions Reporting Benzodiazepine and Narcotic Pain Reliever Abuse at Treatment Entry. December 13, 2012, Substance Abuse and Mental Health Services Administration, Rockville, MD.
15. 15 Jann, M., Kennedy, W.K., Lopez, G., Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics. J Pharm Pract 27:1 (2014), 5–16, 10.1177/0897190013515001.
16. 16 White, J.M., Irving, R.J., Mechanisms of fatal opioid overdose. Addiction 94:7 (1999), 961–972, 10.1046/j.1360-0443.1999.9479612.x.
17. 17 Pattinson, K.T., Opioids and the control of respiration. Br J Anaesth 100:6 (2008), 747–758, 10.1093/bja/aen094.
18. 18 Lee, S.C., Klein-Schwartz, W., Doyon, S., Welsh, C., Comparison of toxicity associated with nonmedical use of benzodiazepines with buprenorphine or methadone. Drug Alcohol Depend 138 (2014), 118–123, 10.1016/j.drugalcdep.2014.02.014.
19. 19 Peirce, G.L., Smith, M.J., Abate, M.A., et al. Doctor and pharmacy shopping for controlled substances. Med Care 50:6 (2012), 494–500, 10.1097/MLR.0b013e31824ebd81.
20. 20 Park, T.W., Saitz, R., Ganoczy, D., Ilgen, M.A., Bohnert, A.S., Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ, 350, 2015, h2698, 10.1136/bmj.h2698.
21. 21 Dasgupta N, Funk MJ, Proescholdbell S, Hirsch A, Ribisl KM, Marshall S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Med. In press. Online September 2, 2015. http://dx.doi.org/10.1111/pme.12907.
22. 22 Rolfs, R.T., Johnson, E., Williams, N.J., Sundwall, D.N., Utah Department of H. Utah clinical guidelines on prescribing opioids for treatment of pain. J Pain Palliat Care Pharmacother 24:3 (2010), 219–235, 10.3109/15360288.2010.503265.
23. 23 Washington Agency Medical Directors Group. Interagency guideline on opioid dosing for chronic noncancer pain. www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf. Published 2010. Accessed July 2, 2015.
24. 24 Kahan, M., Wilson, L., Mailis-Gagnon, A., Srivastava, A., National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations. Can Fam Physician 57:11 (2011), 1269–1276.
25. 25 Paone, D., Dowell, D., Heller, D., Preventing misuse of prescription opioid drugs. City Health Inform 30 (2011), 23–30.
26. 26 Manchikanti, L., Abdi, S., Atluri, S., et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: part 2−guidance. Pain Physician 15(3):suppl (2012), S67–S116.
27. 27 American Geriatrics Society. 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 60:4 (2012), 616–631.
28. 28 Fick, D.M., Cooper, J.W., Wade, W.E., Waller, J.L., Maclean, J.R., Beers, M.H., Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a U.S. consensus panel of experts. Arch Intern Med 163:22 (2003), 2716–2724, 10.1001/archinte.163.22.2716.
29. 29 McLeod, P.J., Huang, A.R., Tamblyn, R.M., Gayton, D.C., Defining inappropriate practices in prescribing for elderly people: a national consensus panel. CMAJ 156:3 (1997), 385–391.
30. 30 Maletta, G., Mattox, K.M., Dysken, M., Guidelines for prescribing psychoactive drugs in the elderly: part 1. Geriatrics 46:9 (1991), 40–47.
31. 31 American Psychiatric Association Task Force on Benzodiazepine Dependency. Benzodiazepine Dependence, Toxicity, and Abuse, 1990, American Psychiatric Publishing, Arlington, VA.
32. 32 Gomes, T., Mamdani, M.M., Dhalla, I.A., et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med 171:7 (2011), 686–691, 10.1001/archinternmed.2011.117.
33. 33 Lavin, R.A., Tao, X.G., Yuspeh, L., Bernacki, E.J., Impact of the combined use of benzodiazepines and opioids on workers’ compensation claim cost. J Occup Environ Med 56:9 (2014), 973–978, 10.1097/JOM.0000000000000203.
34. 34 Park, T.W., Bohnert, A.S., Austin, K.L., Saitz, R., Pizer, S.D., Regional variation in benzodiazepine prescribing for patients on opioid agonist therapy. Psychiatr Serv, 65(1), 2014, 4, 10.1176/appi.ps.201300419.
35. 35 Mellbye, A., Svendsen, K., Borchgrevink, P.C., Skurtveit, S., Fredheim, O.M., Concomitant medication among persistent opioid users with chronic non-malignant pain. Acta Anaesthesiol Scand 56:10 (2012), 1267–1276, 10.1111/j.1399-6576.2012.02766.x.
36. 36 Kao, M.C., Zheng, P., Mackey, S., Trends in benzodiazepine prescription and co-prescription with opioids in the United States, 2002−2009. Pain Med, 15, 2014, 488.
37. 37 Pincus, H.A., Tanielian, T.L., Marcus, S.C., et al. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties. JAMA 279:7 (1998), 526–531, 10.1001/jama.279.7.526.
38. 38 Stafford, R.S., MacDonald, E.A., Finkelstein, S.N., National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 3:6 (2001), 232–235, 10.4088/PCC.v03n0611.
39. 39 Cook, J.M., Marshall, R., Masci, C., Coyne, J.C., Physicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med 22:3 (2007), 303–307, 10.1007/s11606-006-0021-3.
40. 40 Everitt, H., McDermott, L., Leydon, G., Yules, H., Baldwin, D., Little, P., GPs’ management strategies for patients with insomnia: a survey and qualitative interview study. Br J Gen Pract 64:619 (2014), e112–e119, 10.3399/bjgp14X677176.
41. 41 Dunn, K.M., Saunders, K.W., Rutter, C.M., et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 152:2 (2010), 85–92, 10.7326/0003-4819-152-2-201001190-00006.
42. 42 Paulozzi, L.J., Zhang, K., Jones, C.M., Mack, K.A., Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. J Am Board Fam Med 27:3 (2014), 329–338, 10.3122/jabfm.2014.03.130290.
43. 43 Food and Drug Administration. Extended-release (ER) and long-acting (LA) opioid analgesics risk evaluation and mitigation strategy (REMS). www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM311290.pdf. Published December 2014. Accessed June 12, 2015.
44. 44 Trescott, C.E., Beck, R.M., Seelig, M.D., Von Korff, M.R., Group Health's initiative to avert opioid misuse and overdose among patients with chronic noncancer pain. Health Aff (Millwood) 30:8 (2011), 1420–1424, 10.1377/hlthaff.2011.0759.
45. 45 U.S. Department of Veterans Affairs. VA initiative shows early promise in reducing use of opioids for chronic pain. www.va.gov/opa/pressrel/pressrelease.cfm?id=2529. Published February 25, 2014. Accessed June 30, 2015.
46. 46 CDC. Visits to physician offices, hospital outpatient departments, and hospital emergency departments, by age, sex, and race. www.cdc.gov/nchs/data/hus/2012/088.pdf. Published 2012. Accessed June 21, 2015.
47. 47 CDC. Persons with hospital stays in the past year, by selected characteristics: United States, selected years 1997−2012. www.cdc.gov/nchs/data/hus/2012/093.pdf. Published 2012. Accessed June 21, 2015.
48. 48 CDC. Expenses for health care and prescribed medicine, by selected population characteristics: United States, selected years 1987−2010. www.cdc.gov/nchs/data/hus/2014/046.pdf. Published 2014. Accessed June 30, 2015.
49. 49 CDC. Severe headaches or migraine, low back pain, and neck pain among adults aged 18 and over, by selected characteristics: United States, selected years 1997−2013. www.cdc.gov/nchs/data/hus/2012/093.pdf. Published 2012. Accessed June 21, 2015.
50. 50 McLean, C.P., Asnaani, A., Litz, B.T., Hofmann, S.G., Gender differences in anxiety disorders: prevalence, course of illness, comorbidity and burden of illness. J Psychiatr Res 45:8 (2011), 1027–1235, 10.1016/j.jpsychires.2011.03.006.
51. 51 Kessler, R.C., McGonagle, K.A., Zhao, S., et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51:1 (1994), 8–19, 10.1001/archpsyc.1994.03950010008002.
52. 52 Olfson, M., King, M., Schoenbaum, M., Benzodiazepine use in the United States. JAMA Psychiatry 72:2 (2015), 136–142, 10.1001/jamapsychiatry.2014.1763.
53. 53 Reuben, D.B., Alvanzo, A.A., Ashikaga, T., et al. National Institutes of Health Pathways to Prevention Workshop: the role of opioids in the treatment of chronic pain. Ann Intern Med 162:4 (2015), 295–300, 10.7326/M14-2775.
54. 54 Reisfield, G.M., Webster, L.R., Benzodiazepines in long-term opioid therapy. Pain Med 14:10 (2013), 1441–1446, 10.1111/pme.12236.
55. 55 Khong, T.P., de Vries F, Goldenberg JS, et al. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. Calcif Tissue Int 91:1 (2012), 24–31, 10.1007/s00223-012-9603-8.
56. 56 Substance Abuse and Mental Health Services Administration. Emergency department visits involving nonmedical use of the anti-anxiety medication alprazolam. http://archive.samhsa.gov/data/2k14/DAWN153/sr153-alprazolam-2014.pdf. Published May 22, 2014. Accessed June 24, 2015.
57. 57 Sansone, R.A., Sansone, L.A., Doctor shopping: a phenomenon of many themes. Innov Clin Neurosci 9:11–12 (2012), 42–46.
58. 58 Worley, J., Prescription drug monitoring programs, a response to doctor shopping: purpose, effectiveness, and directions for future research. Issues Ment Health Nurs 33:5 (2012), 319–328, 10.3109/01612840.2011.654046.
59. 59 Finklea K, Sacco LN, Bagalman E. Prescription drug monitoring programs. Congressional Research Service: Washington, DC. http://fas.org/sgp/crs/misc/R42593.pdf. Published March 24, 2014. Accessed June 30, 2015.
60. 60 Katz, N., Panas, L., Kim, M., et al. Usefulness of prescription monitoring programs for surveillance—analysis of schedule II opioid prescription data in Massachusetts, 1996−2006. Pharmacoepidemiol Drug Saf 19:2 (2010), 115–123, 10.1002/pds.1878.
61. 61 Rutkow, L., Turner, L., Lucas, E., Hwang, C., Alexander, G.C., Most primary care physicians are aware of prescription drug monitoring programs, but many find the data difficult to access. Health Aff (Millwood) 34:3 (2015), 484–492, 10.1377/hlthaff.2014.1085.